CNS Hodgkin lymphoma

Elizabeth R. Gerstner, Lauren E. Abrey, David Schiff, Andres J M Ferreri, Andrew Lister, Silvia Montoto, Richard Tsang, Eckhard Thiel, Francesc Graus, Dirk Behringer, Gerald Illerhaus, Susan Weaver, Patrick Wen, Alfredo Voloschin, Nancy Lee Harris, Tracy T. Batchelor

Research output: Contribution to journalArticle

Abstract

Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare. As a result, there is limited guidance for clinicians on how to manage these patients. Detailed information was collected on 16 patients, the largest number to date, with meningeal or parenchymal CNS-HL confirmed by histopathology (15) or CSF (1). Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse. Patients received a range of treatments including surgery or radiation alone, radiation with chemotherapy, or chemotherapy alone. Median overall survival for all 16 patients was 60.9 months from first diagnosis of HL (systemic or CNS) and 43.8 months from diagnosis of CNS-HL. Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.

Original languageEnglish
Pages (from-to)1658-1661
Number of pages4
JournalBlood
Volume112
Issue number5
DOIs
Publication statusPublished - Sep 1 2008

Fingerprint

Neurology
Hodgkin Disease
Central Nervous System
Chemotherapy
Radiation
Drug Therapy
Macrophage Colony-Stimulating Factor
Survival
Central Nervous System Diseases
Surgery
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Gerstner, E. R., Abrey, L. E., Schiff, D., Ferreri, A. J. M., Lister, A., Montoto, S., ... Batchelor, T. T. (2008). CNS Hodgkin lymphoma. Blood, 112(5), 1658-1661. https://doi.org/10.1182/blood-2008-04-151563

CNS Hodgkin lymphoma. / Gerstner, Elizabeth R.; Abrey, Lauren E.; Schiff, David; Ferreri, Andres J M; Lister, Andrew; Montoto, Silvia; Tsang, Richard; Thiel, Eckhard; Graus, Francesc; Behringer, Dirk; Illerhaus, Gerald; Weaver, Susan; Wen, Patrick; Voloschin, Alfredo; Harris, Nancy Lee; Batchelor, Tracy T.

In: Blood, Vol. 112, No. 5, 01.09.2008, p. 1658-1661.

Research output: Contribution to journalArticle

Gerstner, ER, Abrey, LE, Schiff, D, Ferreri, AJM, Lister, A, Montoto, S, Tsang, R, Thiel, E, Graus, F, Behringer, D, Illerhaus, G, Weaver, S, Wen, P, Voloschin, A, Harris, NL & Batchelor, TT 2008, 'CNS Hodgkin lymphoma', Blood, vol. 112, no. 5, pp. 1658-1661. https://doi.org/10.1182/blood-2008-04-151563
Gerstner ER, Abrey LE, Schiff D, Ferreri AJM, Lister A, Montoto S et al. CNS Hodgkin lymphoma. Blood. 2008 Sep 1;112(5):1658-1661. https://doi.org/10.1182/blood-2008-04-151563
Gerstner, Elizabeth R. ; Abrey, Lauren E. ; Schiff, David ; Ferreri, Andres J M ; Lister, Andrew ; Montoto, Silvia ; Tsang, Richard ; Thiel, Eckhard ; Graus, Francesc ; Behringer, Dirk ; Illerhaus, Gerald ; Weaver, Susan ; Wen, Patrick ; Voloschin, Alfredo ; Harris, Nancy Lee ; Batchelor, Tracy T. / CNS Hodgkin lymphoma. In: Blood. 2008 ; Vol. 112, No. 5. pp. 1658-1661.
@article{af406f81e3524c328ed41e74d73e3e3c,
title = "CNS Hodgkin lymphoma",
abstract = "Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare. As a result, there is limited guidance for clinicians on how to manage these patients. Detailed information was collected on 16 patients, the largest number to date, with meningeal or parenchymal CNS-HL confirmed by histopathology (15) or CSF (1). Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse. Patients received a range of treatments including surgery or radiation alone, radiation with chemotherapy, or chemotherapy alone. Median overall survival for all 16 patients was 60.9 months from first diagnosis of HL (systemic or CNS) and 43.8 months from diagnosis of CNS-HL. Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.",
author = "Gerstner, {Elizabeth R.} and Abrey, {Lauren E.} and David Schiff and Ferreri, {Andres J M} and Andrew Lister and Silvia Montoto and Richard Tsang and Eckhard Thiel and Francesc Graus and Dirk Behringer and Gerald Illerhaus and Susan Weaver and Patrick Wen and Alfredo Voloschin and Harris, {Nancy Lee} and Batchelor, {Tracy T.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1182/blood-2008-04-151563",
language = "English",
volume = "112",
pages = "1658--1661",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - CNS Hodgkin lymphoma

AU - Gerstner, Elizabeth R.

AU - Abrey, Lauren E.

AU - Schiff, David

AU - Ferreri, Andres J M

AU - Lister, Andrew

AU - Montoto, Silvia

AU - Tsang, Richard

AU - Thiel, Eckhard

AU - Graus, Francesc

AU - Behringer, Dirk

AU - Illerhaus, Gerald

AU - Weaver, Susan

AU - Wen, Patrick

AU - Voloschin, Alfredo

AU - Harris, Nancy Lee

AU - Batchelor, Tracy T.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare. As a result, there is limited guidance for clinicians on how to manage these patients. Detailed information was collected on 16 patients, the largest number to date, with meningeal or parenchymal CNS-HL confirmed by histopathology (15) or CSF (1). Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse. Patients received a range of treatments including surgery or radiation alone, radiation with chemotherapy, or chemotherapy alone. Median overall survival for all 16 patients was 60.9 months from first diagnosis of HL (systemic or CNS) and 43.8 months from diagnosis of CNS-HL. Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.

AB - Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare. As a result, there is limited guidance for clinicians on how to manage these patients. Detailed information was collected on 16 patients, the largest number to date, with meningeal or parenchymal CNS-HL confirmed by histopathology (15) or CSF (1). Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse. Patients received a range of treatments including surgery or radiation alone, radiation with chemotherapy, or chemotherapy alone. Median overall survival for all 16 patients was 60.9 months from first diagnosis of HL (systemic or CNS) and 43.8 months from diagnosis of CNS-HL. Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.

UR - http://www.scopus.com/inward/record.url?scp=52649140954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649140954&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-04-151563

DO - 10.1182/blood-2008-04-151563

M3 - Article

C2 - 18591379

AN - SCOPUS:52649140954

VL - 112

SP - 1658

EP - 1661

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -